Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 6/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 2/20 | 0.32 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.32 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.32 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.31 |
| ▸ | GHSR | Q92847 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5789036 | 0.74 | TLR7 (0.33) | TLR7KDM4EMEN1LMNAKMT2A | |
| SCHEMBL4069055 | 0.74 | PRMT5 (0.34) | PRMT5 | |
| SCHEMBL4520810 | 0.73 | TLR7 (0.34) | TLR7 | |
| SCHEMBL1486453 | 0.71 | TLR7 (0.60) | TLR7 | |
| SCHEMBL5503890 | 0.71 | HDAC1 (0.41) | MEN1KMT2A | |
| SCHEMBL5791352 | 0.69 | HCAR2 (0.32) | KDM4ELMNAAR | |
| SCHEMBL5275376 | 0.68 | TLR7 (0.35) | TLR7MTNR1AMTNR1B | |
| SCHEMBL5276268 | 0.68 | TLR8 (0.42) | — | |
| SCHEMBL5274121 | 0.68 | TLR7 (0.41) | TLR7POLBMEN1KMT2A | |
| SCHEMBL5508094 | 0.67 | TLR8 (0.41) | TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897597-B2 | Aryloxy and arylalkyleneoxy substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-03-01 | — | — | US | disclosed |
| US-20090018122-A1 | Aryloxy and Arylalkyleneoxy Substituted Imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018122-A1 | Aryloxy and Arylalkyleneoxy Substituted Imidazoquinolines | IL2, IFNG, IRF3 | TLR7 45/4885POLB 1965/4885NPC1 2265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.